Vanguard Investments Australia
AGIO icon

Vanguard Investments Australia’s Agios Pharmaceuticals AGIO Stock Holding History

Vanguard Investments Australia’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$502K Hold
13,537
– – ﹤0.01% 1655
2026
Q1 		$458K Buy
+13,537
New +$384K ﹤0.01% 1611

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Vanguard Investments Australia's AGIO Position: Q2 2026 in Review

Vanguard Investments Australia held its Agios Pharmaceuticals (AGIO) position steady in Q2 2026 at 13,537 shares worth $502K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Vanguard Investments Australia first reported a position in AGIO in Q1 2026 and has held it in 2 quarters since. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Vanguard Investments Australia held 13,537 shares of Agios Pharmaceuticals worth $502K as of Q2 2026.
  • Vanguard Investments Australia left its Agios Pharmaceuticals share count unchanged in Q2 2026.
  • Agios Pharmaceuticals made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1655 holding.
  • Vanguard Investments Australia first reported a position in Agios Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.